Search results for " Survival"

showing 10 items of 1946 documents

Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis.

2014

Aims Insulin resistance (IR) is a major risk factor for cardiovascular disease and atherosclerosis. Life-threatening acute events are mainly due to rupture of unstable plaques, and the role of vascular smooth muscle cells (VSMCs) in this process in IR, Type 2 diabetes mellitus, and metabolic syndrome (T2DM/MetS) has not been fully addressed. Therefore, the role of VSMC survival in the generation of unstable plaques in T2DM/MetS and the involvement of inflammatory mediators was investigated. Methods and results Defective insulin receptor substrate 2 (IRS2)-mediated signalling produced insulin-resistant VSMCs with reduced survival, migration, and higher apoptosis than control cells. Silencing…

medicine.medical_specialtyVascular smooth musclePhysiologyCell Survivalmedicine.medical_treatmentMyocytes Smooth MuscleCX3C Chemokine Receptor 1InflammationMice TransgenicBiologyMuscle Smooth VascularInsulin resistanceApolipoproteins EPhysiology (medical)Internal medicinemedicineAnimalsHumansProtein kinase BPI3K/AKT/mTOR pathwayCells CulturedMice KnockoutChemokine CX3CL1Insulinmedicine.diseaseAtherosclerosisIRS2Mice Inbred C57BLAtheromaEndocrinologyDiabetes Mellitus Type 2cardiovascular systemReceptors Chemokinemedicine.symptomInsulin ResistanceCardiology and Cardiovascular MedicineSignal TransductionCardiovascular research
researchProduct

Evaluation of Safety, Tolerability and Efficacy of Temsirolimus in Patients with Relapsed or Refractory Mantle Cell Lymphoma (Rel/Refr Mcl) in Routin…

2014

ABSTRACT Aim: Temsirolimus (TEMS), an mTOR-inhibitor, is approved in the EU for the treatment of patients (pts) with relapsed or refractory (rel/refr) MCL. A pivotal study demonstrated significantly longer progression free survival with TEMS (175 mg weekly for 3 weeks followed by 75 mg weekly) in rel/refr MCL pts compared to investigatoŕs choice therapy (4.8 mo vs 1.9 mo; P = .0009). To evaluate safety and efficacy of TEMS in an unselected patient population during clinical routine, a prospective non-interventional study with TEMS in rel/refr MCL pts is useful. Here we report on interim results of the study. Methods: A German multicenter registry for rel/refr MCL pts treated with TEMS was s…

medicine.medical_specialtybusiness.industryAnemiaHematologymedicine.diseaseTemsirolimusSurgeryOncologyRefractoryTolerabilityInternal medicineRefractory Mantle Cell LymphomaMedicineMantle cell lymphomaProgression-free survivalbusinessAdverse effectmedicine.drugAnnals of Oncology
researchProduct

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myelo…

2018

Abstract Introduction: Mutations localized in the tyrosine kinase domain activation loop of FLT3 (FLT3-TKD), representing point mutations in codon D835/I836 and rarely deletions of codon I836, induce constitutive tyrosine phosphorylation and activation of the receptor tyrosine kinase similarly to FLT3 internal tandem duplication (ITD) mutations. However, the prognostic role of FLT3-TKD in AML, particularly in the presence of NPM1 mutations, is not well established. The phase 3 RATIFY trial [NCT00651261; Stone et al. N Engl J Med. 2017] showed that in combination with standard chemotherapy, midostaurin (PKC412) improved survival outcomes across all 3 FLT3 stratification subgroups (ITD high a…

medicine.medical_specialtybusiness.industryImmunologyComplete remissionImproved survivalCell BiologyHematologyNewly diagnosedPlaceboBiochemistryConsolidation therapy03 medical and health sciencesNPM1 Mutationchemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisFamily medicineMedicineIn patientMidostaurinbusiness030215 immunologyBlood
researchProduct

Lower extremity soft tissue defect reconstruction with the serratus anterior flap

2013

Reconstruction of limb-threatening lower extremity defects presents unique challenges. The selected method must provide adequate coverage of exposed bone, joints, and tendons while maximizing function of the limb. The traditional workhorse flaps, the free latissimus dorsi and rectus abdominis flaps, have been associated with donor site morbidity and bulkiness that can impair rehabilitation. We report a case series (n = 18) in which the free serratus anterior muscle flap and split thickness skin graft (STSG) was used for lower limb soft tissue coverage. Injuries were due to diabetes (9/18), trauma (7/18), and chronic venous stasis (2/18). A 94% flap survival rate was observed and all but one…

medicine.medical_specialtybusiness.industrySerratus anterior muscle flapDefect reconstructionSoft tissueFree flapSerratus anterior flapmedicine.diseaseSurgeryNo donorsVenous stasisMedicineFlap survivalSurgerybusinessMicrosurgery
researchProduct

Perioperative morbidity and renal function in young and elderly patients undergoing elective nephron-sparing surgery or radical nephrectomy for renal…

2010

Objective To analyse renal function, perioperative morbidity and overall survival (OS) in patients aged 65 years treated by radical nephrectomy (RN) or elective nephron-sparing surgery (NSS) for renal tumours > 4 cm. Patients and methods From our database, we identified 829 patients with renal tumours > 4 cm treated by either RN (n = 641) or NSS (n= 188) at our institution between 1981 and 2007. After excluding patients with imperative indication and metastases, we identified retrospectively 81 patients aged 65 years (elderly patients) treated for renal tumours > 4 cm. In all, 36 and 33 patients underwent NSS and 45 and 52 patients underwent RN in the young and elderly group, respectively. …

medicine.medical_specialtybusiness.industryUrologymedicine.medical_treatmentRenal functionPerioperativeurologic and male genital diseasesmedicine.diseaseNephrectomySurgerymedicineOverall survivalCarcinomaNephron sparing surgeryYoung adultbusinessKidney diseaseBJU International
researchProduct

Evaluation of Safety, Tolerability and Efficacy of Temsirolimus in Patients with Relapsed or Refractory Mantle Cell Lymphoma (REL/REFR MCL) in the Us…

2012

ABSTRACT Background Temsirolimus (TEMS), an mTOR-inhibitor, is approved the EU for the treatment of patients (pts) with relapsed or refractory MCL (rel/refr). A pivotal study demonstrated significantly longer progression free survival with TEMS (175mg weekly for 3 weeks followed by 75mg weekly) in rel/refr MCL pts compared to investigatoŕs choice therapy (4.8 mo vs 1.9 mo; P = .0009). To better identify safety and efficacy of TEMS in an unselected patient population during clinical routine a prospective non-interventional study with TEMS in rel/refr MCL-pts was started. Here we report on interim results of the study. Methods A registry for rel/refr MCL pts treated with TEMS was started in G…

medicine.medical_specialtybusiness.industrymacromolecular substancesHematologyTemsirolimusOncologyTolerabilityRefractoryInternal medicinemedicineRefractory Mantle Cell LymphomaIn patientProgression-free survivalLeukocytosismedicine.symptombusinessAdverse effectmedicine.drugAnnals of Oncology
researchProduct

Survival of patients with gastric lymphoma in Germany and in the United States

2015

Background and Aim This study aims to examine survival for gastric lymphomas and its main subtypes, mucosa-associated lymphoid tissue lymphoma (MALT), and diffuse large B-cell lymphoma (DLBCL), in Germany and in the United States. Methods Data for patients diagnosed in 1997–2010 were used from 10 population-based German cancer registries and compared to the data from the US Surveillance, Epidemiology and End Results (SEER) 13 registries database. Patients age 15–74 diagnosed with gastric lymphomas were included in the analysis. Period analysis and modeled period analysis were used to estimate 5-year and 10-year relative survival (RS) in 2002–2010 and survival trends from 2002–2004 to 2008–2…

medicine.medical_specialtyeducation.field_of_studyHepatologyRelative survivalbusiness.industryGastric lymphomaPopulationGastroenterologymedicine.diseaseGastroenterologySurgeryCancer registryLymphomaimmune system diseaseshemic and lymphatic diseasesInternal medicineMedicinebusinesseducationMucosa-associated lymphoid tissueDiffuse large B-cell lymphomaSurvival rateJournal of Gastroenterology and Hepatology
researchProduct

Atteinte de la Muscularis Mucosae dans les tumeurs urothéliales T1 de vessie : facteur pronostique de progression après immunothérapie par BCG

2012

OBJECTIVES: To study the prognostic impact of muscularis mucosae (MM) invasion for pT1 bladder cancer treated by transurethral resection (TUR) and adjuvant Bacille Calmette-Guerin (BCG) intravesical immunotherapy. METHODS: Sixty-six patients treated by BCG intravesical instillations were substaged into pT1a and pT1b, regarding Muscularis Mucosae invasion. Tumor grade, associated carcinoma in situ (CIS), multifocality, tumoral size up to 3cm, BCG maintenance were noted. With a mean follow-up of 50.5±38 months, we studied recurrence, progression, overall and specific survival. Cox's model method was used for multivariate analysis. RESULTS: Tumor recurrence was observed in 30±7% and 43±10% (P=…

medicine.medical_specialtyeducation.field_of_studyPathologyMuscularis mucosaeBladder cancerbusiness.industryUrologymedicine.medical_treatmentCarcinoma in situPopulation030232 urology & nephrologyImmunotherapymedicine.diseaseGastroenterology3. Good healthCystectomy03 medical and health sciences0302 clinical medicineTumor progression030220 oncology & carcinogenesisInternal medicinemedicineProgression-free survivaleducationbusinessProgrès en Urologie
researchProduct

Population‐based study of the treatment and prognosis of carcinoma of the rectum

1997

Background Few population-based studies address the issue of treatment of carcinoma of the rectum (15 cm or less from the anal vcrge) both from surgical and epidemiological aspects. Methods Some 827 patients were analysed in the cancer registry of the Cote-d'Or (Burgundy, France) from 1976 to 1990 (493 931 inhabitants). Results Resection for cure increased from 57.2 per cent before 1981 to 77.0 per cent after 1985 (P <11.001), and the proportion of Dukes A and B cascs from 35.8 to 52.5 per cent (P< 0.001). Among patients resected for cure, continence-preserving resections were performed more frequently during the 1986-1990 period (48.0 per cent) than during the two previous 5-year periods (…

medicine.medical_specialtyeducation.field_of_studyRelative survivalbusiness.industryPopulationRectummedicine.diseaseColorectal surgeryCancer registrySurgerymedicine.anatomical_structureCarcinomaMedicineFecal incontinenceSurgerymedicine.symptombusinesseducationSurvival analysisBJS
researchProduct

Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: F…

2009

Abstract Abstract 4276 Introduction Imatinib mesylate (IM) has shown unprecedented effectiveness in the treatment of Chronic Myeloid Leukemia (CML) patients (pts) in the chronic phase of the disease. As most of the data concerning the efficacy of the drug derive either from a single sponsored trial or from single institution reports, we decided to accrue all CML pts diagnosed in the Italian region of Sicily to the observational SCREEN (Siciliy CML Regional Enterprise) study, to evaluate the hematological, cytogenetic and molecular responses of this unselected population to IM. Patients and Methods Although the study is still ongoing, 173 consecutive CML pts have been enrolled between Januar…

medicine.medical_specialtyeducation.field_of_studybusiness.industryImmunologyPopulationMyeloid leukemiaCell BiologyHematologymedicine.diseaseInterim analysisBiochemistrySurgeryLeukemiaImatinib mesylateMulticenter studyInternal medicinemedicineProgression-free survivaleducationbusinessComplete Hematologic Response
researchProduct